Real-World study tracks darolutamide use in advanced prostate cancer
NCT ID NCT07406282
First seen Feb 26, 2026 · Last updated May 23, 2026 · Updated 10 times
Summary
This study reviews medical records of 1,400 men with metastatic hormone-sensitive prostate cancer (mHSPC) to see how darolutamide is used in everyday urology clinics. It compares two treatment approaches: darolutamide plus hormone therapy alone (doublet) or with chemotherapy (triplet). The goal is to understand patient characteristics, drug use patterns, and outcomes, helping doctors make better treatment decisions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATIC NEOPLASMS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Precision Point Specialty LLC PPS Analytics, a Specialty Networks LLC Company
RECRUITINGCleveland, Ohio, 44114-2619, United States
Conditions
Explore the condition pages connected to this study.